Cancer therapies can have a profound, and often permanent, effect on the cardiovascular system. Patients at high risk of cardiotoxicity should be identified before treatment, closely monitored, and given cardioprotective agents to reduce adverse events. The authors of this Review discuss the complications that can occur as a result of cancer therapy, and emphasize the importance of assessing both the cardiotoxicity and benefits of cancer treatment.
- Michael S. Ewer
- Steven M. Ewer
